Buradasınız

Anasayfa » Content

Vasküler endotelyal büyüme faktörü ile uterin miyom ve korelasyon matriks metalloproteinaz-2 Ekspresyonu anjiyogenez

Expression of vascular endothelial growth factor and matrix metalloproteinase-2 in uterine leiomyoma and correlation with angiogenesis

Journal Name:

  • Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2011

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objective: Leiomyoma is the most common tumor of the uterus. Angiogenic factors and proteases may play role in the growth of uterine leiomyoma.The aim of our study was to investigate the expression of vascular endothelial growth factor (VEGp) and matrix metalloproteinase-2 (MMP-2) in uterine leiomyoma and their possible relation to microvessel density (MVD). Material and methods: Material for the study comprised parafin-embedded tissue sections of uterine leiomyomas and corresponding myometrium derived from 50 hysterectomized women. VEGp, MMP-2 and CD34 expression was investigated immunohistochemically. Semiquantitative analysis of the immunostainings for VEGp and MMP-2 was performed. MVD was calculated by counting of CD34 positive vascular endothelial cells. Results: Expression of VEGp and MMP-2 was significantly higher in leiomyomas than corresponding myometrium (p=0.001). The CD34 labeling showed decreased MVD in leiomyomas compared with myometrium (p<0.05). There was no correlation between VEGp and MMP-2 staining and MVD. Conclusion: These data suggested that VEGp and MMP-2 may play role in the development of uterine leiomyomas. Mechanisms other than promotion of angiogenesis may contribute to this disease process.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Leyomiyom uterusun en sık görülen tümörüdür. Uterin leyomiyomun büyümesinde anjiyogenik faktörler ve proteazlar rol oynayabilir. Çalışmamızın amacı uterin leyomiyomlarda vasküler endotelyal büyüme faktörü (VEGp) ve matriks metalloproteinaz-2 (MMP-2) ekspresyonunu araştırmak ve mikrodamar yoğunluğu (MVD) ile olası ilişkilerini belirlemekti. Gereç ve yöntemler: Çalışma materyali leyomiyom nedeni ile opere edilmiş 50 hastanın leyomiyom ve normal miyometriyumunu içeren parafin bloklardan oluşuyordu. VEGp, MMP-2 ve CD34 ekspresyonu immünohistokimyasal olarak çalışıldı. VEGp ve MMP-2' ye ait immünohistokimyasal yöntemle elde edilen bulgular semikantitatif analiz ile değerlendirildi. MVD ise, CD34 pozitif vasküler endotelyal hücreleri sayarak hesaplandı. Bulgular: Leyomiyomlardaki VEGp ve MMP-2 ekspresyonu normal miyometriyuma göre anlamlı olarak daha yüksek bulundu (p=0.001). CD34 boyaması MVD' nun leyomiyomlarda miyometriyuma göre daha az olduğunu gösterdi (p<0.05). VEGp ve MMP-2 boyanması ile MVD arasında korelasyon saptanmadı. Sonuç: Bu bulgular uterin leyomiyomların patogenezinde VEGp ve MMP-2' nin rol oynayabileceğini düşündürmüştür. Bu hastalığın gelişim sürecine anjiyogenez dışındaki bazı faktörler de katkıda bulunabilir.
FULL TEXT (PDF): 
PDF icon arastirmax-vaskuler-endotelyal-buyume-faktoru-ile-uterin-miyom-korelasyon-matriks-metalloproteinaz-2-ekspresyonu-anjiyogenez.pdf
  • 3
86-91
  • Turkish

REFERENCES

References: 

1. Zaloudek C, Hendrickson MR. Mesenchymal tumors ofthe uterus. In: Kurman RJ, ed. Blaustein' s Pathology of the Female Genital Tract (5th Ed) New York, Springer-Verlag, 2002; 561-615.
2. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22(4): 571-88.
3. Balcı O, Çolakoğlu MC, Özdemir S. Benign diseases ofthe uterine corpus. Türkiye Klinikleri J Surg Med Sci 2007; 3(40): 27-35.
4. Stewart EA, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update 1996; 2(4): 295-306.
5. Kumar V, Abbas AK, Fausto N. Tissue Renewal and Repair: Regeneration, Healing, and Fibrosis. In: Kumar V, Abbas AK, Fausto N, eds. Robbins Pathologic Basis ofDisease (7th Ed) China, Elsevier Saunders, 2005;
87-118.
6. Hulboy DL, Rudolf LA, Matrisian LM. Matrix metalloproteinases as mediators of reproductive function. Mol Hum Reprod 1997; 3(1): 27-45.
7. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274(31): 21491-4.
8. Coussens LM, Werb Z. Matrix metalloproteinases and the development ofcancer. Chem Biol 1996; 3(11):
895-904.
9. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005; 9(2): 267-85.
10. Noyes RW, Hertig AT, Rock JR. Dating the endometrial biopsy. Am J Obstet Gynecol 1975; 122(2): 262-3.
11. Sun WH, Sun YL, Fang RN, Shao Y, Xu HC, Xue QP, et al. Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. Jpn J Clin Oncol 2005; 35(12): 707-13.
12. Weidner N, Semple JP, Welch WR, Folkman J. Tumour angiogenesis and metastases- correlation in invasive breast carcinoma. N Engl J Med 1991; 324(1): 1-8.
13. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992;23(7): 755-61.
14. Torry RJ, Rongish BJ. Angiogenesis in the uterus: potential regulation and relation to tumor angiogenesis. Am J Reprod Immunol 1992; 27(3-4): 171-9.
15. Zhang L, Rees MCP, Bicknell R. The isolation and long term culture of normal human endometrial epithelium and stroma: expression of mRNAs for angiogenic polypeptides basally and on oestrogen challenge. J Cell Sci 1995; 108(Pt 1): 323-31.
S.D.Ü. Tıp pak.
Derg
. 2011:18(3)/86-91
91
Tokyol, VEGp
an
d MMP-2 expression in uterine leiomyoma
16. Harrison-Woolrych ML, SharkeyAM, Charnock-Jones DS, Smith SK. Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab 1995; 80(6):
1853-8.
17. Dixon D, He H, Haseman JK. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect 2000; 108(suppl 5): 795-802.
18. Poncelet C, Madelenat P, Feldmann G, Walker F, Darai E. Expression of von Willebrand' s factor, CD34, CD31, and vascular endothelial growth factor in uterine leiomyomas. Fertil Steril 2002; 78(3): 581-6.
19. Özçakır HT, Baytur Y, Giray G, Uyar Y, Özbilgin K, Çağlar H. Leiomyom ve normal myometriumda immunohistokimyasal vasküler endotelyal growth factor (VEGF) ekspresyonu. Türk Fertilite Dergisi 2003;11(4):299-304.
20. Gentry CC, Okolo SO, Fong LF, Crow JC, Maclean AB, Perrett CW. Quantification ofvascular endothelial growth factor-A in leiomyomas and adjacent myometrium. Clin Sci 2001; 101(6): 691-5.
21. Fujita M. Histological and biochemical studies of collagen in human uterine leiomyomas. Hokkaido IgakuZasshi 1985; 60(4): 602-15.
22. Wegrowski Y, Bellon G, Quereux C, Maquart F-X. Biochemical alterations of uterine leiomyoma extracellular matrix in type IV Ehlers-Danlos syndrome. Am J Obstet Gynecol 1999; 180(4): 1032-4.
23. Bogusiewicz M, Stryjecka-Zimmer M, Postawski K, Jakimiuk AJ, Rechberger T. Activity of matrix metalloproteinase-2 and -9 and contents oftheir tissue inhibitors in uterine leiomyoma and corresponding myometrium. Gynecol Endocrinol 2007; 23(9): 541¬6.
24. Wolanska M, Sobolewski K, Bankowski E, Jaworski S. Matrix metalloproteinases ofhuman leiomyoma in various stages oftumor growth. Gynecol Obstet Invest 2004; 58(1): 14-8.
25. Casey R, Rogers PA, Vollenhoven BJ. An immunohistochemical analysis of fibroid vasculature. HumReprod2000; 15(7): 1469-75.
26. Walocha JA, Litwin JA, Miodonski AJ. Vascular system ofintramural leiomyomata revealed by corrosion casting and scanning electron microscopy. Hum Reprod 2003; 18(5): 1088-93.

Thank you for copying data from http://www.arastirmax.com